Cardiol Therapeutics (CRDL) Income towards Parent Company (2020 - 2026)

Cardiol Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$6.9 million for Q1 2026.

• Quarterly Income towards Parent Company fell 21.58% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.4 million (up 6.05% YoY) and the FY2025 annual result came in at -$24.1 million, up 13.91% from the prior year.
• Income towards Parent Company was -$6.9 million for Q1 2026 at Cardiol Therapeutics, up from -$7.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$4.7 million in Q2 2023 and bottomed at -$10.4 million in Q3 2024.
• A 5-year average of -$6.9 million and a median of -$6.3 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company surged 43.66% — and 2024, when it slumped 81.51%.
• Cardiol Therapeutics' Income towards Parent Company stood at -$6.4 million in 2022, then gained by 10.51% to -$5.7 million in 2023, then slumped by 81.51% to -$10.4 million in 2024, then gained by 28.64% to -$7.4 million in 2025, then increased by 6.29% to -$6.9 million in 2026.
• Business Quant data shows CRDL's Income towards Parent Company at -$6.9 million in Q1 2026, -$7.4 million in Q3 2025, and -$6.1 million in Q2 2025.